Physician agency, consumerism, and the consumption of lower-limb MRI scans

Michael Chernew\textsuperscript{a}, Zack Cooper\textsuperscript{b,∗}, Eugene Larsen Hallock\textsuperscript{c}, Fiona Scott Morton\textsuperscript{d}

\textsuperscript{a} Harvard Medical School and the NBER, 180 Longwood Avenue, Boston, MA, 02115, United States
\textsuperscript{b} Yale University and the NBER, 77 Prospect Street, New Haven, CT, 06521, United States
\textsuperscript{c} Columbia University, 420 West 118th, New York, NY, 10027, United States
\textsuperscript{d} Yale University and the NBER, 165 Whitney Avenue, New Haven, CT, 06511, United States

\textbf{A R T I C L E  I N F O}

Article history:
Received 26 November 2019
Received in revised form
28 November 2020
Accepted 30 December 2020
Available online 19 January 2021

\textbf{JEL classification:}
I1
I11

Keywords:
Provider prices
Shopping
Price transparency
Vertical integration
Agency

\textbf{A B S T R A C T}

We study where privately insured individuals receive planned MRI scans. Despite significant out-of-pocket costs for this undifferentiated service, privately insured patients often receive care in high-priced locations when lower priced options were available. The median patient in our data has 16 MRI providers within a 30-minute drive of her home. On average, patients bypass 6 lower-priced providers between their homes and their actual treatment locations. Referring physicians heavily influence where patients receive care. The share of the variance in the prices of patients’ MRI scans that refer fixed effects (52 percent) explain is dramatically greater than the share explained by patient cost-sharing (< 1 percent), patient characteristics (< 1 percent), or patients’ home HRR fixed effects (2 percent). In order to access lower cost providers, patients must generally diverge from physicians’ established referral patterns.

© 2021 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

Over the last two decades, policy-makers and private firms in the United States (US) have attempted to reduce health care costs by increasing patients’ out-of-pocket cost exposure. From 2007 to 2017, out-of-pocket health care spending in the US increased by approximately 60 percent (Rae et al., 2019). At present, 55 percent of workers have a deductible of $1000 or more, one in four are enrolled in a plan with a deductible of at least $3,000, and average out-of-pocket costs in 2017 were $779 (Kaiser Family Foundation, 2019; Rae et al., 2019). However, to date, the simple prediction from price theory - that increased cost sharing together with accessible pricing information would induce patients to change where they consume care - has not been well supported by the empirical evidence on patient behavior. Specifically, there is scant empirical evidence that when they are enrolled in a deductible plan or given access to price transparency tools, patients increasingly attend low cost care locations for health care services that are relatively undifferentiated (Brot-Goldberg et al., 2017; Desai et al., 2017; Mehrotra et al., 2017).

Using data from a large commercial insurer, we study where individuals age 19–64 with private health insurance,
high out-of-pocket cost exposure, and access to a price transparency tool receive planned lower-limb MRI scans. We analyze the frequency that patients bypassed receiving care at lower price MRI locations and, instead, received care at more expensive providers. We focus, in particular, on quantifying the relationship between referring physicians and the locations where their patients received imaging services.

This paper is, at its core, descriptive. We describe the money (theirs and the payers’) that patients leave on the table, identify the factors that explain the variation in the price of the care patients received, and then identify the referral patterns of orthopedic surgeons. Finally, we explore whether the apparent referral patterns of vertically-integrated orthopedists differ from those of independent orthopedists.

Advanced imaging studies (e.g. MRI and CT scans) constitute approximately 3 percent of health care spending in the US and are a convenient setting to explore the relative influence of physician preferences and pre-established referral patterns on where patients receive care. Previous studies have found that over 40 percent of health care services are potentially shoppable by consumers (White and Eguchi, 2014; Frost and Newman, 2016). To be shoppable, these studies stipulate that patients must be able to have more than one option over where they receive care, have the ability to schedule when they will receive care, and be able to compare price and quality across multiple providers. Among the range of services that scholars and policy-analysts consider shoppable, planned lower-limb MRI scans are among the least differentiated health care services with respect to clinical quality, are unlikely to produce adverse events, are relatively expensive, and can generally be scheduled in advance of care. They should, therefore, be among the health care services most amenable to patient ‘shopping’. As a result, we view our results as a likely lower bound on the extent to which physicians’ preferences and established referral patterns influence where patients receive care.

Outside of health care, economists generally believe that utility-maximizing consumers are capable of effectively shopping for simple goods and services (Samuelson, 1997). Even for more complex goods, such as automobiles, there is evidence that consumers can capably observe and navigate tradeoffs between complex characteristics, like fuel efficiency, horsepower, and cabin luxury (Berry et al., 1995). As early as Arrow (1963), however, it has been argued that uncertainty and information asymmetry in the health care sector give rise to “the special economic problems of medical care,” including those stemming from the agency relationship between physician and patient. It is this agency relationship and, in particular, the influence of referring physicians, that we focus on in this analysis.

Within our sample, the prices of lower-limb MRI providers vary extensively within regions. For example, the MRI provider in the 80th price percentile in the typical hospital referral region (HRR) is 1.74 times more expensive than the MRI provider in the 20th percentile. Much of this variation is a function of the type of facility where patients receive their imaging study: the average hospital-based lower-limb MRI scan in our data had a price of $1,475.41, while non-hospital-based lower-limb MRIs were, on average, priced at $644.52. Our analysis suggests that the clinical quality of MRI scans does not vary substantially across providers. A low quality scan would need to be repeated. However, of the 50,409 MRIs in our data, only 0.004 percent of scans (2 scans in total) were repeated within a 90-day window. We will return to the issue of the quality of reading the scans later in the paper.

Despite the variation in MRI scan prices across providers, patients often receive care in high-priced locations when lower priced options are available. Fig. 1 is emblematic of the patterns we observe in our data. Fig. 1 shows the price of MRI providers in a large urban hospital referral region (HRR).1 Each column is a provider that delivered at least one lower-limb MRI in 2013. The height of the columns (left vertical axis) shows the average price of an MRI. The darker columns are hospitals, while the lighter columns are non-hospital MRI providers. The dots (right vertical axis) show the number of cases treated at each provider. In this particular HRR, the provider in the 80th percentile of prices in the area is 3.1 times more expensive than the provider in the 20th percentile. The most expensive provider is 8 times as expensive as the lowest-cost provider. Moreover, the highest priced provider has the highest volume of MRI scans in this HRR.

Across the entirety of our sample, ignoring capacity constraints and general equilibrium (GE) effects, we estimate that if patients went to the lowest priced provider within a 60-minute car drive from their homes, total MRI spending would be reduced by 55.16 percent, insurer contributions would decrease by 61.32 percent ($333.55), and patient out-of-pocket costs would be reduced by 44.24 percent ($135.76). We refer to this counterfactual as the ‘maximum potential savings’.

Fig. 1. Variation in MRI Prices in a Densely Populated Hospital Referral Region.
Notes: Each bar is a provider address. Bar height indicates the average price of an MRI at that provider’s location (left Y-axis). Grey bars indicate hospitals, while white bars are non-hospitals. The black dots denote the number of lower extremity MRIs in our sample performed at that provider address (right Y-axis). These statistics are derived from the same sample of MRIs described in Table 1.
Ultimately, a significant portion of the maximum potential savings available to patients and insurers is accessible without patients having to travel farther for care. For example, total spending on lower-limb MRI scans would be reduced by 35.83 percent if patients accessed the lowest priced provider available within the same drive time as the facility where they received care. This result occurs because patients, on average, bypassed 6 lower-priced providers between their home and the location where they received their scan. In addition, while the average patient in our sample had $307 in out-of-pocket costs, we do not find that individuals exposed to cost-sharing went to lower priced providers.

We then carry out an ANOVA to understand the factors that explain the largest share of the variance in the price of individuals’ lower-limb MRI scans. We study the 35,819 lower-limb scans delivered to our sample of patients in 2013 and analyze the relative contribution of patient cost sharing (whether patients were over their deductible or not), patient characteristics (their Charlson comorbidity score, age, sex, and race), HRR fixed effects, and fixed effects for the orthopedic surgeon who ordered their MRI. We find referring physician fixed effects explain the largest share of the variance in the price of MRI scans that patients received. Based on our ANOVA, referrer fixed effects in our analytic sample explain 82 percent of the explained variance (52 percent of the overall variance) in the price of an MRI scan. Indeed, referrer fixed effects explain a significantly larger share of the variance in the price of MRIs than patient residential ZIP code (ZCTA) fixed effects, HRR fixed effects, patient characteristics, or patient cost sharing. To illustrate the null and show that the share of spending explained by referrers is not a mechanical effect of introducing a large number of fixed effects, we run our ANOVA on each of 1000 draws of our data in which we randomly assign all patients from our analytic sample to referring physicians in their HRRs. Across the 1000 runs of our ANOVA on randomly assigned data, referrer fixed effects capture, on average, 9.7 percent of the variance in the price of patients’ MRI scans. We interpret this finding as evidence that referring physicians (including the staff at their practice) heavily influence where their patients receive care.

We then provide some of the first analysis of physicians’ referral. We find that most orthopedic surgeons’ patients receive care at a small group of imaging locations even when there are generally many available options. For example, while the median patient in our sample had 16 MRI providers within a 30-minute drive from her home, the median referring orthopedic surgeon in our sample had 80 percent of her patients receive care from a single imaging provider. Further, the median referring orthopedic surgeon had zero patients attend the lowest cost provider within either 30- or 60-minutes from the patient’s home. We interpret these facts as evidence that orthopedic physicians tend to refer their patients to only a small number of MRI locations.

Ultimately, a crucial finding from our analysis is that in order to significantly lower their out-of-pocket costs and reduce total MRI spending, patients must diverge from the established referral pathways of their referring physicians. This suggests that there is a role for insurers to nudge physicists to refer in a more cost-effective manner and generate greater price elasticity for MRI scans.

The apparent referral decisions of physicians may be suboptimal for two reasons. First, referring physicians may lack information on the prices of the facilities where they are sending their patients, and second, physicians may be motivated to refer patients to specific providers for reasons other than quality or patient costs. For example, in the last decade, there has been a marked increase in the share of physician practices that are owned by hospitals (Baker et al., 2014). Existing evidence suggests that physicians who are vertically-integrated with a hospital are more likely to refer patients to a hospital (Baker et al., 2016). We find patients with a vertically integrated referring physician had scans that were 36.3 percent more expensive and were 27 percent more likely to receive a hospital-based scan. There was no difference in patient characteristics between those who went to referring physicians who typically sent patients to high cost locations and those who sent patients to low cost locations.

Our results have implications for the academic literature and for policy-makers. Existing models of patient choice often use the distance between patients and providers as the primary determinant of where patients receive care (see Gowrisankaran et al., 2015; Capps et al., 2003; Ho, 2006 as examples). While this may be appropriate for emergency care, our results suggest that, particularly for planned care, economists should integrate the effect of physician agency into their choice models. Ultimately, our results suggest that a patient’s referring physician is the strongest determinant of the cost of the MRI scan that a patient receives and whether they receive a hospital-based MRI scan.2

On the policy front, while consumer theory suggests that greater price transparency and out-of-pocket cost exposure in health care could lead to large efficiency gains, our work shows that these standard incentives do not perform well in real world health care markets. We show that this is, in part, because of the influence of agents. As a result, incentivizing providers to make more efficient referrals or aligning physician and patient incentives are likely more effective approaches to reducing health care costs than exclusively targeting patients with monetary and non-monetary incentives. Finally, our work also suggests that because of the outsized influence referring physicians have on where patients receive care, regulators must consider the implications of vertical transactions between physician groups and hospitals on vertical foreclosure and health spending.

This paper is structured as follows. In Section 2, we give background on insurance plan design, describe the use of price transparency tools, and highlight the role of physician agency in health care decision-making. In Section 3, we describe our data, how we identify prices, and how we identify where patients could have alternatively received care,

---

2 Our results should not be misinterpreted as stating that a patient-provider distance does not matter. Distance does matter. We observe patients travelling 26 minutes, on average, for care. They do not, for example, travel an hour. However, our results suggest that inside some reasonable distance bound, physician preferences and their established referral patterns have more influence than patient-provider distance.
and what they would have paid for care at those locations. We present our results in Section 4. We offer a discussion of our results and conclude in Section 5.

2. Background on price transparency, health care shopping, and physician agency

Advanced imaging studies – magnetic resonance imaging (MRI) and computed tomography (CT) scans – account for approximately 3 percent of US health spending (Iglehart, 2009). There has been significant interest in the potential for patients to shop for advanced imaging studies, like lower-priced lower-limb MRI scans, because they are high priced and relatively undifferentiated. However, most analysis of the impact of health care transparency tools on patient shopping for advanced imaging services have found that they have had a very modest effect, in part, because they are rarely used by patients.

Lieber (2017) and Whaley et al. (2014) estimate that the actual users of price transparency tools save approximately 15 percent on the price of imaging services. However, Brown (2019a) found that only 8 percent of consumers having an MRI scan used New Hampshire’s transparency website before accessing care. Likewise, Lieber (2017) found that, at a large restaurant chain, only 12 percent of the employees searched for price information at least once. Similarly, Desai et al. (2017) found that at a sample of large private firms, fewer than 10 percent of individuals offered the transparency tool used it. These results echo findings from a national survey that suggested only three percent of non-elderly individuals in the U.S. had compared prices across providers before receiving care (Mehrotra et al., 2017) and work by Sinaiko and Rosenthal (2016), which found that less than 2 percent of Aetna customers used the firm’s price transparency tool.

Both Lieber (2017) and Brown (2019b) suggest that the use of transparency tools would increase if individuals were more directly exposed to the price of health care services. This proposition is supported by theory modeled by Dionne and Eckhoudt (1984) and Akin and Platt (2014). Brown (2019b) estimates that if individuals had a 50 percent co-insurance rate, this would lead to a 38 percent increase in the number of consumers using price shopping tools. Likewise, Lieber (2017) estimated that individuals who met their deductibles were 1.5 percentage points less likely to search for price information. However, when Brot-Goldberg et al. (2017) examined the impact of switching individuals at a large firm from first dollar coverage to high deductible health plans, they did not observe an increase in price shopping in the year the switch took place or in the second year after the switch occurred. In fact, virtually all the reduction in spending that Brot-Goldberg et al. (2017) observed following the introduction of deductibles came from patients reducing the quantity of health care consumed.

In the face of lackluster results from increasing deductibles and introducing price transparency tools, some private employers have introduced reference pricing schemes to steer individuals to lower cost providers and have experimented with paying patients to price shop. In a reference pricing program, beneficiaries are enrolled in plans where the payer will only fund care up to the price of the provider in the (for example) 60th percentile of prices in the region where the patient lives. These programs involve even greater potential out-of-pocket exposure for patients. A recent analysis found that individuals in a reference pricing program received MRIs that were 12.5 percent less expensive than matched individuals that were not in a reference price program (Robinson et al., 2016). Similarly, in a rewards program run by a collection of employers, employees were given $25 to $500 checks if they went to lower priced providers. Among individuals with the opportunity to be rewarded for shopping, 8.2 percent of patients used a price transparency tool, there was a 1.3 percentage-point increase in the probability of receiving care from a lower-priced provider, and average prices of services consumed were reduced by 2.1 percent (Whaley et al., 2019). While the program led to a 4.7 percent reduction in the price of MRI scans and a 3.4 percentage point increase in the use of lower-rice MRI providers, the program did not influence the price of CT scans (Whaley et al., 2019).

One understudied potential explanation for why most consumers do not generally price shop for relatively undifferentiated services is the weight patients place on advice from their referring physicians about where to receive care. Survey data suggests that patients rely heavily on the advice of their physicians when determining where to receive treatment (Harris, 2003; Tu and Lauer, 2008). Patients can be uncertain about many aspects of their care, including what services are necessary and the quality of providers from whom they could receive treatment. This, as Arrow (1963) noted, gives rise to the need for physicians to serve as agents for their patients.

Decades of literature focusing on health care and other sectors has explored the agency relationship and found that agency is often imperfect (Hubbard, 1998; Levitt and Syverson, 2008). Within the health care sector, there is a large literature that suggests the presence of supplier induced demand, where providers motivated by financial gain encourage patients to utilize services those patients do not need (Gruber and Owings, 1996). Physicians may also gain directly or indirectly from the referrals they make. In the 1990s, laws were passed that prohibited physicians from referring patients to facilities where they had an ownership stake (these are often referred to as the Stark laws). However, the law allows physicians who own imaging equipment to benefit directly from referring patients to receive scans within their own practice. Physicians may also gain indirectly from making referrals within the system where they are employed (Baker et al., 2016). Indeed, there is anecdotal evidence of vertically integrated health systems punishing physicians who refer patients outside the system (Kowalczyk, 2018).

If physicians were perfect agents for patients, we would expect aspects of care that are important to the patient (such as out-of-pocket costs) to influence referral choices even if the patient had no direct input into the decision. However, the referrals that physicians make may differ from the choices that would be made by a perfectly informed patient both because the physician may not be fully informed about the patient preferences and patients’ out-of-pocket costs and because maximizing patient wel-
fare may not be physicians’ only objective when making referrals. Survey evidence suggests that physician referrals are often influenced by physicians’ past experiences with providers, physicians’ perceptions about access to care, and their personal familiarity with their referral locations (Kinchen et al., 2004; Barnett et al., 2012).

3. Data, identifying MRI scans, calculating prices, and building patient choice sets

3.1. Primary and secondary data

Our primary data set is composed of insurance claims data provided by a large national insurer that covers tens of millions of lives per year and has coverage in all fifty US states. Our main analysis uses data from 2013. We built an analytic sample of claims for the most common MRI scan in our data: lower-limb MRIs performed without contrast.\(^3\) We identify lower-limb MRIs in our data as those cases involving either a physician or facility claim with a Current Procedural Terminology (CPT) code of 73721. We identify whether or not a scan was performed in a hospital using the place of service code on a claim.

Our goal is to identify shoppable, homogeneous MRI scans. As a result, we limit our analysis to MRI scans taken during in-network visits where no health care services were provided on the claim other than the “reading” and “taking” of the MRI (this excludes 14 percent of observations). We also exclude MRIs performed during an inpatient stay, or as part of an emergency episode, since patients in these cases are unlikely to be able to actively choose where to receive care (this accounts for less than 1 percent of cases). We limit our analysis to individuals age 19–64, exclude cases where there were coordinated benefits (i.e. our insurer co-funded the care with another insurer), (10 percent of cases), exclude cases where the MRI provider was more than a two hour drive from the patient’s home ZIP code (3 percent of cases), and exclude cases performed at out-of-network facilities (2 percent of cases).\(^4\) We also restrict our analysis to MRI scans performed on individuals who were continuously enrolled for at least three months in a point of service (POS) insurance product (the modal insurance product offered by our data contributor). We focus on individuals with POS plans because network breadth and the prices insurers have negotiated with providers may differ across the types of insurance products our data supplier offers. Applying these restrictions to our data leaves us with an initial sample of 88,292 MRI scans.

3.2. Identifying patients’ referring physicians

In order to identify the referring physicians for each lower-limb MRI scan in our data, we use the claims history of each patient in our sample to find patients who receive a lower-limb MRI scan and have at least one office visit with an orthopedic surgeon in the three months prior to the taking of an MRI scan.\(^5\) We restrict our analysis to patients who saw an orthopedist in the three months prior to a scan so that we can assume that the orthopedist a patient saw before a scan is the referring physician. Approximately 60 percent of patients in our sample saw an orthoped within three months of a lower-limb MRI scan. We assume that the orthopedist a patient saw before a scan is the referring physician.\(^6\)

Restricting our analysis to patients who saw an orthopedist three months before a lower-limb MRI scan eliminates 36,909 of 88,292 cases. The remaining 51,383 cases are divided as follows. In 94 percent of these cases, patients only saw a single orthopedic surgeon before a scan took place. In 6 percent of cases, however, the patient saw two or more different orthopedic surgeons before a scan occurred. For such patients, we identify whether the patient saw an orthopedic surgeon after the scan. We assume that the orthopedic surgeon who saw the patient both before and after the scan was the referring physician. This captures 68 percent of the cases where patients saw two or more orthopedists before a scan. We exclude the remaining 971 cases (2 percent of 51,383 cases) that cannot be categorized this way.\(^7\) After excluding those observations and three observations for which the patient was the only person in their HRR to receive a lower-limb MRI scan, we are left with a final analytic sample size of 50,409 scans.\(^8\) When we transition to analyzing the behavior of referring physicians, we further limit our analysis to referring physicians who ordered at least 5 lower-limb MRIs for patients in our sample population. Doing so excludes 14,577 patient observations.

To identify whether referring physicians are part of a vertically integrated organization, we merge in data from SK&A. The SK&A physician-level dataset we employ identifies the group or hospital that owns a practice at which

\(^3\) MRI scans can be carried out with or without contrast. MRIs with contrast have higher image clarity and can better show soft tissue, but require the patient to be injected with a contrasting agent called gadolinium. In this analysis, we focus on lower-limb MRI scans performed without contrast and exclude those performed with contrast. MRI scans without contrast make up the vast majority of scans in our data.

\(^4\) Our data divides patients into five-year age bands. However, individuals aged 18 years are lumped in with individuals under age 18. Since 18 year-old individuals could not be distinguished from minors, we focused on individuals aged 19 to 64. We do not include any providers that were out-of-network with any patients. As a result, we are constructing a conservative choice set for most patients and may be potentially excluding a modest number of providers who may be in-network.

\(^5\) We identify an orthopedic surgeon by the physician’s National Provider Identifier (NPI) number.

\(^6\) It is possible that we falsely assume that an orthopedist who treated a patient in the three months before a lower-limb MRI scan was the referring physician for the MRI scan. This would generate measurement error in our estimates of the share of the variance in MRI prices explained by referring physicians. In general, this measurement error would lead us to underestimate the share of the variance in MRI prices explained by referring physicians.

\(^7\) These include cases where 1) the patient saw multiple orthopedists both before and after a scan; 2) the patient visited with multiple orthopedists before the scan but none afterwards; and 3) the patient saw multiple orthopedists before the scan and saw one or more orthopedists after the scan who were not the same orthopedists as the ones they saw before the MRI.

\(^8\) We do this to remain consistent with rules in our data use agreement that preclude us from analyzing HRRs with very small numbers of cases.
3.3. Measuring provider prices

Our data include the amounts patients paid for the taking and reading of their MRIs via co-insurance, co-payments, and payments under their deductibles. Our data also include the prices our data contributor has negotiated with facilities and physicians for the taking and reading of MRIs.

We use place of service codes to identify whether an MRI scan was delivered inside or outside of a hospital. For hospital-based MRIs, we observe a physician claim for the “reading” of the MRI scan and a facility claim for the “taking” of the MRI scan (this is identified via the presence of a CPT code of 73721). We calculate the total price of a hospital-based MRI scan as the sum of the service lines on the physician and facility claims with a CPT code of 73721 that occurred on the same date with the same patient identifier. For non-hospital-based MRIs, providers typically bill for both the taking and reading of an MRI scan on a physician claim. As a result, we calculate the total price of a non-hospital-based MRI scan as the physician claim with a CPT code of 73721.

3.4. Constructing patient choice sets and estimating payments at alternate providers

For each patient who underwent an MRI in our sample, we construct a choice set of MRI providers within a 60-minute drive of each patient’s home. To do so, we begin by identifying every provider that delivered an MRI scan to a patient in our sample. Next, we calculate travel times between each patient’s home ZIP code (ZCTA) and the addresses of all providers within 100 miles of the patient’s ZIP code. This is done using the online routing API (application programming interface) provided by “Here”, a commercial mapping company. The “Here” software uses average traffic patterns and user reported data to estimate travel time, by car, between two locations. By using travel time instead of distance, we allow patients in rural areas to travel farther in the same amount of time than patients in densely populated cities.

The price of an MRI at each provider is calculated as the average of the prices of scans at that provider during our time period. The price we calculate includes the payments for the taking and reading of an MRI scan. Our combined price is the allowed amount, so it includes both the patient and insurer contributions to total payment for a scan. We then estimate what patients and our data contributor would pay for a lower-limb MRI scan at alternate, lower-priced providers.\(^9\)

While we do not directly observe beneficiaries’ plan characteristics, we can infer plan benefit designs from our data. To infer what patients would have paid at lower-priced locations, we rely on two facts. First, when moved to a lower priced provider, a patient will never pay more towards her deductible than she did on her original episode. Second, individuals pay the entirety of the price for care under their deductible and coinsurance rates can be inferred for all patients who exceed their deductible and need to pay coinsurance.\(^11\) Our task of inferring co-insurance is made easier by the fact that none of the patients in our sample have plans that charge patients fixed co-payments.

3.5. Money left on the table

For every case in our data, we identify the lowest priced alternative provider within a 60-minute drive from the patient’s home ZIP code. This is a mechanical calculation and it ignores capacity constraints and GE effects. We then calculate the “money left on the table” by patients and insurers. The “money left on the table” is the amount of money the patient and the insurer would have saved, respectively, had the patient received an MRI scan at this lower priced location.

3.6. Patient cost sharing

We observe patients’ out-of-pocket costs for each MRI they consume. In practice, patients in our sample are enrolled in plans with deductibles, co-insurance, and an out-of-pocket maximum. Patients in our sample do not have fixed co-payments. The individual deductibles, co-insurance rates, and out-of-pocket maximums in our sample vary across patients’ insurance plans.

In later analysis, we analyze the extent to which variance in patients’ out-of-pocket cost exposure explains the variance in the price of the MRI scans they receive. In this analysis, our primary measure of patient out-of-pocket cost sharing is an indicator for whether or not patients were over their out-of-pocket maximums at the time their scans were taken (and hence had no out-of-pocket cost exposure). We use this measure because, in practice, the proportion of costs borne by patients can be mechanically linked to the price of the MRIs individuals consumed. For example, because of the structure of the benefits design in our sample, the more expensive an MRI provider an individual attends, the greater her actual cost sharing measured

\(^9\) We can link more than 95 percent of the referring physicians in our sample to the SK&A data using the orthopedic surgeon’s NPI. We assume physicians we cannot link to the SK&A data are not in vertically integrated practices. Our results are also robust to the alternative assumption that those physicians’ practices are vertically integrated.

\(^11\) We assume the coinsurance rate \(c\) that we observe for patient \(i\) who received care at provider \(j\) would be the same co-insurance rate that patient \(i\) would pay at other locations. This is an assumption that our data contributor has told us applies in virtually every case in the data. The insurer in our data does not have co-payments for MRI scans.
in dollars. In addition to constructing a binary indicator of whether a patient has non-zero cost sharing, we also construct three additional cost sharing measures: 1) a continuous measure of patients’ out-of-pocket costs measured in dollars; 2) indicator variables for whether a patient had no cost sharing, some cost sharing (but not the full price of the scan), or were exposed to the entirety of the price of an MRI scan; and 3) the co-insurance rate faced by individuals in our sample who consumed an MRI scan when they are above their deductible, but below their out-of-pocket maximum and therefore faced coinsurance payments. We show that our decomposition results are robust to all four measures of cost sharing.

3.7. Transparency tool use

Our data contributor provides all their beneficiaries (i.e. all individuals in our sample) with free access to an online and app accessible price transparency tool that allows policy-holders to search for providers for given treatments and procedures and sort by distance, the price paid by the insurer, and their out-of-pocket costs. The tool links to claims data, so users can observe their personalized out-of-pocket payments at each location as a function of their plan design and year-to-date spending. The price transparency tool would allow users to identify accurate prices at each potential care location. We merge data on the use of this tool into our analysis. The transparency tool data includes a patient ID (which we use to link to the claims data), the date of the search, and information on what type of procedure the patient searched for. As a result, we can identify users who searched for MRI prices prior to receiving an MRI scan.

3.8. Provider quality

In this analysis, we assume that the taking and reading of MRIs is undifferentiated across providers from the patient’s perspective. While the actual taking of the MRI scan is largely undifferentiated, there is evidence of differentiation in the reading of MRI scans across radiologists. For example, Briggs et al. (2008) found that in 13 percent of neurological MRI scans, there was a major difference in diagnosis when a specialist radiologist reviewed the findings of a general radiologist. However, most evidence on diagnostic radiology errors have been observed in the documentation of cancers (Brady, 2017). We focus on analysis of lower-limb MRI scans following a referral by an orthopedic surgeon. As a result, radiologists in our sample are generally looking for structural anomalies (e.g. torn ligaments), not subtle evidence of a cancer. Moreover, 84 percent of patients in our sample had follow-up visits with orthopedic surgeons in the six months after the taking of their MRI. Orthopedists tend to review MRI results themselves before they initiate surgery and Kim et al. (2008) and Figueiredo et al. (2018) found no difference when scans were read by orthopedists versus radiologists. Recall that we limit our sample to patients who see an orthopedist 3 months before their scan and whose scan is ordered by an orthopedist. Thus, the sample of patients we analyze will experience the “reading quality” of their orthopedist, not the facility where the scan is taken. For this reason, we assume that the MRI scan service we study is undifferentiated with respect to clinical quality across providers.

4. Results

4.1. Descriptive statistics

As shown in Table 1, the total price (i.e. sum of allowed amounts on both physician and facilities claims) of the average MRI in our data is $850.85. Twenty-five percent of MRIs in our sample were performed in hospitals. Hospital-based MRIs have an average price of $1,475.41 and cost significantly more than non-hospital-based scans, which have an average price of $644.52.

On average, the patients in our data contribute $306.86 to the cost of MRIs, while the insurer pays $543.99. Twenty-
two percent of patients in our data paid for the entirety of their MRI, 54 percent paid some, but not the full cost, of their scan, and 24 percent had zero out-of-pocket costs. Of those individuals who had cost sharing, 31 percent had health care costs over $5000 in the three months after the taking of the scan, 38 percent had health care costs over $5000 in the six months after the taking of the scan, and 19 percent had health care costs over $10,000 in the six months after the taking of the scan.

As we illustrate in Table 1, the median patient in our sample attends a provider that is approximately a 22-minute car ride from her home. We also find that the median patient had 16 MRI locations within 30-minutes of her home. In 2.7 percent of cases, the patient received an MRI on the same day he or she saw an orthopedist.

### 4.2. Within region variation in MRI prices

There is significant variation in the price of MRI providers within regions, which we define using HRRs. As we illustrate in Table 2, the median HRR has 10 providers in 2013. Across the 302 HRRs in our sample, the median ratio between the 80th and 20th percentile provider prices is 1.74. Likewise, the median coefficient of variation in within HRR MRI provider prices is 0.444. In 89 percent of HRRs, the highest-priced provider within the HRR is a hospital. Notably, despite the fact that hospital-based MRIs tend to be approximately 2.3 times as expensive as MRIs performed outside of a hospital, in 25 percent of HRRs the highest volume MRI provider is a hospital. We find qualitatively similar variance when we look at the price dispersion present within hospital service areas (HSAs).

#### 4.3. Maximum potential savings

We use our data to calculate how much a patient and her insurer could save if she received an MRI scan from the lowest priced provider within a 60-minute drive from her home instead of where she currently received care. While these estimates ignore GE effects and capacity constraints, they give a sense of the potential savings available if patients attended lower cost providers. We refer to these savings as the ‘maximum potential savings.’

Table 3 shows that the maximum potential savings for patients and insurers is substantial. As we illustrate, if patients attended the lowest priced provider within an hour drive from their homes, there would be a mean savings per case of $469.31 and a reduction in MRI spending of 55.16 percent. Our data includes over $100 million in total spending on lower-limb MRI scans and approximately one billion dollars in spending on MRI scans of all types, so this reduction is non-trivial. Patient out-of-pocket costs would decrease, on average, by 44.24 percent from $306.86 to $171.10. Likewise, insurers would lower their average spending on each lower-limb MRI by 61.32 percent, from $543.99 to $210.44.

#### 4.4. Association of MRI prices with quality, distance, and out-of-pocket costs

When economists write down choice models, the attributes of health care providers that patients are assumed to value typically include quality, distance from home, and price. We analyze, in turn, the extent to which...
each of these factors are associated with the patterns we observe.

The quality dimension manifests itself in the reading of the scan, which is done by the orthopedists in our setting. The remaining measure of clinical quality is only whether the MRI scan is correctly taken or needs to be repeated. However, of the 50,409 MRI scans in our data, only two were repeated within 90 days.

Likewise, we find that patients can access lower-priced providers and obtain significant savings without traveling farther than they already went for care. In Table 4, we test the share of the maximum potential savings that would be available if patients traveled no farther than they already went for care, 15-minutes farther, 30-minutes farther, and 45-minutes farther. As we illustrate, if patients attended the lowest price provider reachable in the time they traveled to reach their original providers, out-of-pocket costs could be reduced by 28 percent, insurance spending could be reduced by 41 percent, and total spending on lower-limb MRIs could be reduced by 36 percent. As a result, 65 percent of the maximum potential savings outlined in Table 3 is available without patients having to travel farther for care. This level of savings is possible because patients had, on average, six providers with lower MRI prices than the location where they actually received care within the same travel-time radius.12

When we compare the price of MRI scans delivered to patients with and without cost sharing, we do not find that those exposed to the price of their scan went to lower priced providers. As we illustrate in Appendix Table 1, controlling for patient characteristics and patient HRR fixed effects, patients with price exposure (those below their out-of-pocket maximum at the time their scan was taken) had slightly more expensive MRI scans than patients who had no price exposure. As we illustrate in Appendix Table 2, this result is robust to including referrer fixed effects in our estimation. Likewise, as we illustrate in Appendix Table 3, when we limit our analysis to patients who had to pay coinsurance at the time of their scan (e.g. individuals over their deductible but under their out-of-pocket maximum), we do not find that individuals facing higher co-insurance rates (e.g. those that, because of their plan design, pay a higher portion of the price of the scan) receive lower priced MRI scans. As we illustrate in Appendix Table 4, this result is also robust to including referring physician fixed effects.

One potential explanation for this result could be that because of the structure of insurance plans, individuals may have spot prices (i.e. the price they pay when they access care) that differ markedly from their shadow prices (i.e. the expected true price given that some individuals will exceed their out-of-pocket maximum) (Aron-Dine et al., 2015). Past studies have found that when faced with these nonlinear contracts (e.g. commercial health insurance plans with high up front cost-sharing and then out-of-pocket maximums or Medicare Part D prescription drug plans with a gap in coverage known as a “donut hole”), individuals respond more sharply to the spot price, not the shadow price (Aron-Dine et al., 2015; Einav et al., 2015; Dalton et al., 2020; Brot-Goldberg et al., 2017).13

We do not observe that individuals with high future health spending but non-zero spot prices behave identically to individuals with zero out-of-pocket costs. In Appendix Table 5, we subdivide patients with cost exposure into those who have health care costs above and below $5,000 in the three months after they received care. A threshold of $5,000 was chosen as most plans from our insurer have out-of-pocket maximums of $5,000. For many individuals, health care costs over $5,000 in the three months after a scan would mean they likely faced a shadow price of zero for their MRI scan. This result is robust when we split those with cost sharing into groups with above and below $5,000 in future health care costs in the six months after their scan (Appendix Table 6), those with cost sharing into groups with above and below $5,000 in future health care costs in the 12 months after their scan (Appendix Table 7), and those with above and below $10,000 in future health care costs in the three, six, and 12 months after their scan (Appendix Tables 8–10).

Of note, as we illustrate in Appendix Table 11, very few individuals searched for the price of an MRI scan before receiving the service. Of the 50,409 lower-limb MRI scans in our sample, patients used the price transparency tool

---

12 This is not to say that distance does not matter. Patients travel, on average, 26 minutes to where they ultimately receive care. If distance did not matter, we would find higher travel distances and that patients bypassed more than six local, lower priced providers.

13 Aron-Dine et al. (2015) find that individuals do respond to shadow prices.
supplied by the insurer prior to receiving care in only 375 cases (0.74 percent). This result is consistent with previous analysis from Desai et al. (2017) that few privately insured individuals use price transparency tools before accessing care.

4.5. Identifying the factors that explain the variation in MRI prices and money left on the table

In this section, we carry out an analysis of variance (ANOVA) to identify the factors that explain variance in the price of patients’ MRI scans and better understand the factors influencing where patients receive care. We identify the share of the variance of lower-limb MRI scan prices, total amount of money left on the table, and whether an MRI scan is performed in a hospital. In our ANOVA, we include controls for patients’ out-of-pocket price exposure (a binary indicator of whether patients faced cost-sharing for their scan), patient demographic characteristics (year of birth, Charlson comorbidity score, race, and sex), fixed-effects for patients’ home HRR, and fixed-effects for patients’ referring physicians. Later, we show these results are robust to other measures of patient cost sharing.

Our results suggest that referring physicians heavily influence where patients receive care. As we illustrate in Table 5, referring fixed-effects explain the largest share of the variance in the price of MRIs, money left on the table, and whether a patient received a hospital-based MRI scan. Indeed, referring fixed effects explain 52.5, 51.5, and 55.1 percent of the variance in each variable, respectively.\textsuperscript{14}

One concern might be that the high partial $R^2$ for referring physicians in our ANOVA is mechanically driven by the large number of referring physician fixed effects. To address this concern, we run an ANOVA separately on 1000 draws of our data, where we randomly assign every patient in our sample to referring physicians in the same HRR, maintaining the numbers of referrals per physician, and identify the share of the variance explained by referring fixed effects. Results from this exercise are presented in Fig. 2. As it illustrates, the mean share of the variance in the price of patients’ lower-limb MRI scan explained by referring physicians when we randomly assign patients to physicians in their HRR is 9.7 percent (the mean share of the variance explained by referring fixed effects estimated from 1000 random draws also explains 9.7 percent of the variance in the money left on the table and the probability of a patient receiving an MRI scan at a hospital).\textsuperscript{15} The 5th and 95th percentile of the variance in share of patients’ MRI scans explained by referring fixed effects is 9.2 percent and 10.1 percent, respectively. The partial $R^2$ estimate for referring physician fixed effects that we report in Table 5 – 52.5 percent – is well above the partial $R^2$ estimated on referring fixed effects in our randomization exercise, showing that approximately 42.77 percent (52.47 – 9.7) of the variance captured by referring fixed effects in our ANOVA

\begin{table}
\centering
\caption{ANOVA of MRI Prices, Money Left on the Table, and Whether a Patient Received a Hospital-Based Scan.}
\begin{tabular}{|l|cc|cc|cc|}
\hline
 & \multicolumn{2}{c|}{Total amount paid} & \multicolumn{2}{c|}{Money left on the table} & \multicolumn{2}{c|}{Prob. hospital-based MRI} \\
 & (1) Partial $R^2$ & (2) P-Value & (3) Partial $R^2$ & (4) P-Value & (5) Partial $R^2$ & (6) P-Value \\
\hline
Patient cost sharing & 0.0013 & 0.0000 & 0.0012 & 0.0000 & 0.0029 & 0.0000 \\
Patient Charlson score & 0.0005 & 0.0123 & 0.0005 & 0.0192 & 0.0003 & 0.1683 \\
Patient sex & 0.0000 & 0.9920 & 0.0000 & 0.8217 & 0.0000 & 0.8224 \\
Patient year of birth & 0.0004 & 0.1307 & 0.0003 & 0.3599 & 0.0006 & 0.0160 \\
Patient race & 0.0002 & 0.1742 & 0.0002 & 0.1702 & 0.0001 & 0.3024 \\
Patient HRR F.E. & 0.0187 & 0.0000 & 0.0180 & 0.0000 & 0.0175 & 0.0000 \\
Referring orthopaedist F.E. & 0.3247 & 0.0000 & 0.3146 & 0.0000 & 0.3505 & 0.0000 \\
\hline
\end{tabular}
\end{table}

Notes: This table presents the partial $R^2$ from an analysis of variance (ANOVA) of factors in explaining MRI prices, the amount of money patients could save themselves and their insurer had the patient gone to the minimum cost provider within 60-minutes driving time of their homes, and the probability that a patient received a hospital-based MRI. This table relies on the same sample of patients described in Table 1. We additionally limit the analysis to patients whose referring orthopaedists made at least 5 referrals in 2013. This reduces the number of referring orthopaedists in the sample from 10,839 to 3427 and reduces the sample size by 14,577 to 35,832 MRIs. Lastly, we eliminate all observations that is a singleton in any factor variable category. This reduces the sample size by 13 to 35,819 MRIs. Patient cost sharing is a binary variable which indicates whether a patient had any cost exposure. We identify a patient’s referring orthopaedist by analyzing 3-months of claims history for each patient before their MRI occurred. If a patient saw a physician NPI with a specialty of orthopedic surgeon, then we assign this orthopaedist’s NPI as the patient’s “referring orthopaedist.” Appendix Table 12 re-runs this ANOVA analysis using patient ZCTA fixed effects in lieu of patient HRR fixed effects.

\textsuperscript{14} In Appendix Table 12, we carry out a similar decomposition using an alternative approach, taking MRI price, money left on the table, and an indicator for whether a patient had a hospital-based lower-limb MRI as dependent variables in separate regressions. We then sequentially add in controls for patient characteristics, patient cost sharing fixed effects, patient home HRR fixed effects and referring fixed effects, and then report the corresponding $R^2$ for each regression. Using this alternative decomposition strategy, we still find that referring physicians have significant influence over where patients receive care and the amount of money left on the table. As we illustrate in Column (6) of Appendix Table 12, including patient controls, patient cost sharing fixed effects, and fixed effects for patients’ home HRR explains 24.4 percent of the price of MRIs, 23.3 percent of money left on the table, and 18.7 percent of whether a patient received a hospital-based MRI. Notably, however, as we illustrate in Column (8), adding referring fixed effects raises the $R$-squared in each regression to 0.641, 0.628, and 0.635, respectively. Under this alternative decomposition strategy, this implies that even after controlling for the HRR in which a patient lives, referring fixed-effects explain an additional 39.7 percent of the variance in the price of MRIs, 39.5 percent of the variance in money left on the table, and 44.8 percent of the variance in whether a patient received a hospital-based MRI scan.

\textsuperscript{15} We obtain an $R^2$ of 9.6, 9.6, and 9.6 percent, respectively, for referring fixed effects when we run 1,000 draws on data where we randomly assign patients to any referring physician in the US.
cannot be explained by the mechanical effect of including a large number of referrer fixed effects.

As an alternative approach to illustrate that our results are not highly sensitive to the number of referrals per orthopod, we measure the share of the variance explained by referrer fixed effects when we restrict our sample to orthopods that referred 8 or more patients (the median number of referrals), 10 or more (the 62nd percentile), 12 or more (the 75th percentile) or 20 or more (the 91st percentile). These results are presented in Appendix Table 13. Across these four specifications, referrer fixed effects explain 49.3, 48.1, 47.7, and 44.0 percent of the variance in MRI prices, respectively.

We also illustrate that this result is robust to a range of alternative specifications. First, as we illustrate in Appendix Table 14, this result remains robust when we substitute fixed effects for the ZIP code where the patient lives for fixed effects for the HRR where the patient lives. In this specification, the share of the variance explained by referrer fixed effects is 48.9 percent.

Second, as we discussed in Section 3.6, since there is no perfect measure of cost sharing, we carry out our decomposition results using three alternative measures of patient cost sharing and illustrate that, irrespective of our cost sharing measure, we consistently find that referrer fixed effects explain a large share of the variance in the price of patients MRI scans. First, in Appendix Table 15, we measure a patient’s cost sharing using indicator variables for whether the patient had zero cost sharing, had non-zero cost sharing but did not pay the full cost of the scan, or paid the full price of the scan. When cost sharing is measured using these three categorical variables, cost sharing explains 2.4 percent of the variance in the price of lower-limb MRI scans that patients receive (as opposed to 0.13 in our main specification, where cost sharing is defined using a binary indicator of cost exposure or not) and referrer fixed effects explain 51.81 percent of the variance (rather than 52 percent in our main specification). Second, in Appendix Table 16, we illustrate that our main results are robust to measuring patient cost sharing using a continuous measure of patient cost sharing. When measured using a continuous measure of cost sharing, cost sharing explains 5.29 percent of the variance in the price of patients’ lower-limb MRI scans and referrer fixed effects explain 49.93 percent of the variance. Third, in Appendix Table 17, we illustrate that our main results are robust when we proxy for out-of-pocket cost exposure by using an individual’s coinsurance rate and limit our analysis to individuals who made coinsurance payments. When cost sharing is measured as a patient’s coinsurance rate, cost sharing explains less than 0.001 percent of the variance in the price of patients’ lower-limb MRI scans and referrer fixed effects explain 60.54 percent
of the variance. Collectively, across all our measures of cost sharing, the share of the variance in patients’ MRI prices captured by referrer fixed effects ranges between 49.93 percent and 60.54 percent.

Finally, a portion of our sample is enrolled in an insurance plan that includes prior authorization of MRI scans. However, based on conversations with our data vendor, the prior authorizations were not binding. To that end, we see patients who had a prior authorization denied, but who still received an MRI scan funded by our payer. We employ two strategies to illustrate that the prior authorization process is not driving our results using data from 2014 (the only year we have prior authorization data). At baseline, as we illustrate in Appendix Table 18, we observe that referrer fixed effects explain 51.5 percent of the variance in the price of MRI scans in 2014 (versus 52.5 percent in 2013). In 2014, we observe that 68 percent of patients are enrolled in a plan with prior authorization. In Appendix Table 19, we carry out our main decomposition across the 2014 data, but include an indicator for whether the patient was enrolled in a plan with prior authorization. Being in a prior authorization plan explained less than one percent of the variance in the amount paid for MRI scans and referrer fixed effects explain 51.5 percent of the variance in MRI prices. In Appendix Table 20, we show our main decomposition results for 2014 in Columns (1) and (2) then include the decomposition results for patients in 2014 enrolled in a plan with prior authorization (Columns (3) and (4)) and without prior authorization (Columns (5) and (6)). The share of the variance in MRI scan prices explained by referrer physician fixed effects does not meaningfully differ for patients enrolled in plans with and without prior authorization.

4.6. Referring physicians, prices, and money left on the table

The median referring orthopedic surgeon in our analytic sample made eight referrals for lower-limb MRIs in 2013 (Table 6). The median number of providers from which the patients of an orthopedic surgeon in our sample received MRIs was two (e.g. 80 percent of the median orthopedist’s patients received care from 2 locations), with the modal MRI provider for an orthopedic surgeon’s patients capturing 80 percent of imaging referrals from that surgeon (e.g. 80 percent of the modal orthopedist’s patients received care from 1 location).

As we illustrate in Table 7, in order for patients and insurers to access a large portion of the potential savings, for the most part, patients need to diverge from their referring physicians’ established referral patterns – e.g. they need to receive care from locations where a physician’s patients have not historically received MRI scans. For example, if all patients received an MRI from the modal locations where their orthopedists’ patients historically received care, it would result in only a 10.72 percent reduction in MRI spending and achieve only 19.62 percent of the maximum potential savings.

One potential concern is that patients who require high cost or hospital-based MRIs might endogenously select into orthopedic surgeons with particular referral patterns. That is, referral patterns could reflect patient preferences and characteristics as opposed to reflecting providers’ preferences. While we cannot rule this out entirely, to illustrate that this is unlikely to be the case, we identify the characteristics of patients at orthopedists who send no patients for hospital-based scans (Column (1) in Appendix Table 21) (50 percent of referring physicians our sample) and the characteristics of patients at the 25 percent of orthopedists who send more than 50 percent of their patients for hospital-based scans (Column (2) in Appendix Table 21). Likewise, we identify the characteristics of patients who received referrals from orthopedists with mean prices in the bottom 25 percent of the distribution (Column (4) in Appendix Table 21) in their HRR and those in the top 25 percent of the distribution (Column (5) in Appendix Table 21) in their HRR. As we illustrate, there are not significant differences in patient characteristics across these groups.

The ownership structure of the practices where referring physicians work is also strongly associated with where patients receive care and the price of that care. Within our sample, as we describe in Table 6, 14 percent of orthopedic surgeons worked in hospital-owned practices. Fig. 3 shows for each orthopedic surgeon in our data, the share of the surgeon’s patients she sent from her practice to a hospital to receive a lower-limb MRI scan. There is significant heterogeneity in this outcome. Vertically integrated physicians are more likely to send patients for hospital-based scans. As we illustrate in Table 6, among non-integrated referring physicians, the mean orthopedic surgeon sent 19 percent of her patients for a hospital-based scan. By contrast, the mean vertically-integrated referring physician sent 52 percent of her patients for a hospital-based MRI.

One argument in favor of vertical integration between physicians and hospitals is that it could increase care coordination (Baicker and Levy, 2013). In our context, for example, orthopedic surgeons in vertically-integrated...
organizations might have more seamless access to the results of their patients’ MRI scans via electronic medical records and their patients might be able to receive a scan without having to seek care at a different location. While this is a possibility we cannot exclude, because the cases we examine are not emergencies, there is time to get the scan to the orthopedist without any adverse impact on the health of the patient. Paying a higher price for vertical integration solely to get better transfer of the scan is not likely to be warranted considering that it would have a negligible impact on clinical quality of care.

Table 8 presents results from a cross-sectional regression in which each observation is an MRI scan and the dependent variable is either the total price of an MRI, the patient contribution, the insurer contribution, the money left on the table, an indicator for whether a patient had a hospital-based scan, or an indicator for whether an MRI scan was repeated. In addition to controlling for patient characteristics and the patient’s HRR, we include an indicator for whether a patient’s referring physician is part of a hospital-owned practice. While these results are not causal, we observe that patients with a vertically integrated referring physician were 27 percentage points more likely to receive a hospital-based MRI and had scans that were $276.52 more expensive. This results in an additional $88.50 in out-of-pocket costs, $188.02 more spending by insurers, and another $269.14 left on the table.

5. Discussion and conclusion

We show that despite having access to a price transparency tool and often significant out-of-pocket cost exposure, patients consuming planned lower-limb MRI scans leave significant money on the table when receiving this undifferentiated service. If patients attended the lowest priced provider within the distance they already traveled for care, they could have reduced their out-of-pocket costs by $84.37 (27.49 percent) and lowered insurer spending by $220.49 (40.53 percent). This, in part, reflects that the mean patient in our sample travelled past six lower-priced providers en route to where they ultimately received care.

While consumer theory suggests that greater price transparency in health care could lead to large efficiency gains, realizing those gains is complicated by the centrality of the agency relationship between physicians and their patients. Because of uncertainty over treatment and significant information asymmetries between patient and provider, patients often rely on the medical professionals treating them for advice. Consistent with the emphasis placed on the physician’s role as an agent for the patient (e.g. Arrow, 1963), we find that a patient’s referring physician is the strongest determinant of the cost of the MRI scan that a patient received, the money they left on the table, and whether or not the patient received a hospital-based MRI scan. In our decomposition, referring physician fixed effects explain 82 percent of the explained variance in price of an MRI a patient received (52 percent of the total variance).

We observe that patients of the median orthopedist in our sample received care at 2 MRI locations and that the modal location where patients received a scan captured 80 percent of where an orthopedist’s patients received a scan. The implication of this finding is that many patients will need to be diverted from the pre-established referral pathways of their physicians to obtain cheaper MRIs.
These results indicate the need for insurers to work with physicians themselves, rather than exclusively loading incentives on patients, to reduce spending.

One caveat to our analysis is that while we are able to identify referring physicians, we do not observe what occurs during office visits (e.g. we do not observe patient doctor communication). As a result, we cannot identify with certainty whether physicians themselves directed patients to receive care at specific locations, whether someone in the physician’s practice besides the physician directed patients to receive care at those locations, or whether there are preferences common across all a physician’s patients that led them to receive care from the same imaging providers. In practice, we believe that our refer- rer fixed effects are capturing the influence of physicians and their practice on patient referrals. This interpretation of our findings is consistent with qualitative work that has found that patients rely heavily on physician advice when deciding where to receive care (Harris, 2003; Tu and Lauer, 2008).

Patients who were treated by an orthopedic surgeon working in a hospital-owned practice received more expensive MRI scans, left more money on the table, and were 27 percent more likely to receive a hospital-based scan. Changing the referral patterns of physicians will be challenging when the physicians work for hospitals that offer expensive MRIs and the physicians are rewarded for keeping referrals within the system where they work.

Relative to other health care services, lower-limb MRI scans are relatively undifferentiated with respect to quality. Likewise, because we focused on planned (non-emergent) procedures among a population with easy access to a price transparency tool, patients had ample opportunity to compare providers’ prices and determine where to receive care. As a result, we view this analysis as providing a lower bound on the extent to which physician preferences and their established referral patterns influence where patients receive care. While it is possible that patients become more attentive to where they receive care as the risks associated with their care increase, we think it is unlikely that, even in those circumstances, physician advice would carry less weight vis-à-vis referral locations than it carries relative to the setting we are examining in this study.

Our work has direct implications for the study of health care markets. Most models of how patients choose where to receive care do not explicitly model the role of referring physicians and often assume that the distance between patients and providers is the primary determinant of where patients receive care. While a patient’s distance to their provider does influence where a patient receives care, for care where individuals rely on the advice of their referring physicians, referring physicians’ preferences may outweigh the effects of cost-sharing and differences in travel time (particularly relatively short differences in distance across providers) in determining treatment locations. Our work suggests that economists should integrate the impact of agency into models of patient choice, particularly in non-emergent settings.

On the policy front, this work has direct implications for antitrust enforcement. Over the last two decades, there has been a marked increase in the vertical integration of hospitals and physicians (Scott et al., 2017). Our work is consistent with the literature that demonstrates that when physician practices are owned by hospitals, it can influence physicians’ referral patterns and expose patients to higher out-of-pocket costs. We quantify the fiscal impact of that integration, and more broadly the consequences of decisions to bypass less expensive providers, in a reasonably homogeneous clinical area.

Our work is also informative about the role of demand side cost sharing and the need for incentives for physicians. Over the last 20 years, much of the focus for insurers has been on shifting benefits design and relying on demand side cost sharing to drive patients to consume health care more efficiently. However, Brot-Goldberg et al. (2017) found that deductibles are a blunt tool that reduce health care spending, but do not induce individuals to price shop. We highlight a potential explanation for Brot-Goldberg et al.’s (2017) results. Their results suggest that demand side cost sharing may reduce the rates that individuals access care (with uncertain impacts on welfare); our results suggest that once individuals meet with their physician, in the case of lower-limb MRIs, they rely heavily on their physician’s advice about where to receive subsequent care. Because patients appear to struggle to identify the prices of scans at potential MRI providers and put a high weight on the

Table 8
The Association Between Vertical Integration, Scan Price, Referral Locations, and Money Left on the Table.

<table>
<thead>
<tr>
<th>(1) Total amount paid ($)</th>
<th>(2) Patient contribution ($)</th>
<th>(3) Insurer contribution ($)</th>
<th>(4) Money left on the table ($)</th>
<th>(5) Prob. hospital-based MRI</th>
<th>(6) Prob. MRI was repeated</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vertically integrated referrer</td>
<td>276.52*** (33.50)</td>
<td>88.50*** (12.39)</td>
<td>188.02*** (25.80)</td>
<td>269.14*** (33.83)</td>
<td>0.27*** (0.04)</td>
</tr>
<tr>
<td>Omitted Category: MRIs where the referrer was not vertically-integrated with a hospital</td>
<td>760.74</td>
<td>282.09</td>
<td>478.65</td>
<td>396.42</td>
<td>0.16</td>
</tr>
<tr>
<td>Mean of Omitted Category</td>
<td>35.819</td>
<td>35.819</td>
<td>35.819</td>
<td>35.819</td>
<td>35.819</td>
</tr>
<tr>
<td>Obs.</td>
<td>270.04</td>
<td>0.0993</td>
<td>0.1674</td>
<td>0.2601</td>
<td>0.2231</td>
</tr>
<tr>
<td>R²</td>
<td>0.1674</td>
<td>0.2601</td>
<td>0.2231</td>
<td>0.0021</td>
<td></td>
</tr>
</tbody>
</table>

Notes: * p < 0.10, ** p < 0.05, *** p < 0.01. These regressions use the sample of MRIs described in Table 5 (i.e. we limit the sample of MRIs to ones where the referring orthopedist made at least 5 referrals and we do not include singleton patient HRRs - this reduces the sample size from 50,409 to 35,819). The regressions are run at the patient-level with standard errors clustered around providers. The regressions include controls for patient characteristics, including sex, race, year of birth, and 6-month Charlson comorbidity score. We also include patient HRR fixed effects. We regress several outcome variables on two dummy variables: One denotes if the referring orthopedist is vertically integrated with a hospital and the second denotes if we do not know if the referring orthopedist is vertically integrated with a hospital (i.e. one of the 143 orthopedists whose NPI did not appear in the SK&A data).
advise of their physician, the share of the variance in MRI prices explained by patient cost sharing is low. Though targeted programs and benefit designs, such as reference pricing or rewards programs, may alter treatment locations, our results suggest the need for policymakers and, in particular, insurers to incentivize physicians to make more efficient referrals, and for firms to steer patients towards physicians who make efficient referrals. Previous work has found that when physicians are incentivized to be mindful of the costs of their referrals, this can lead to significant savings (Ho and Pakes, 2014). Likewise, evaluations of public and commercial alternative payment models that incentivize physicians to shop find that redirecting changing physician incentives can generate significant savings (Carrol et al., 2018; Song et al., 2019). In short, price conscious referring physicians are likely to be crucial for raising the price elasticity of MRI scans and many other health care services.

Acknowledgements

We received helpful feedback on this paper from Jason Abaluck, Steve Berry, Zarek Brot-Goldberg, Stuart Craig, Leemore Dafny, and Kate Ho. We also appreciate helpful comments from Kate Bundorf and two anonymous referees. This project received financial support from the Commonwealth Fund, the National Institute for Health Care Management Foundation, Arnold Ventures, the Jameel Poverty Action Laboratory, and the University of Toulouse. We benefited from exceptional research assistance from Charles Gray, Hao Nguyen, and Harriet Jean. The opinions expressed in this paper and any errors are those of the authors alone. For additional questions, please contact Zack Cooper (zack.cooper@yale.edu).

Appendix A. Supplementary data

Supplementary material related to this article can be found in the online version, at https://doi.org/10.1016/j.jhealeco.2021.102427.

References


